导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.63% | 1352/4773 |
| 近一周 | -2.66% | 2779/5462 |
| 近一月 | -5.22% | 3109/5421 |
| 近一季 | -9.08% | 3095/5209 |
| 近半年 | -6.18% | 3032/4920 |
| 近一年 | 9.57% | 1082/4366 |
| 近两年 | 79.15% | 820/2954 |
| 近三年 | 42.64% | 664/2253 |
| 成立以来 | 62.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.15% 1036/4961 |
20.15% 1250/5312 |
- - |
- - |
| 2025 | 34.06% 1081/4813 |
2.38% 1388/3635 |
2.14% 1823/4076 |
26.09% 1364/4524 |
1.68% 1267/4813 |
| 2024 | 7.73% 1628/3463 |
-2.63% 1395/2808 |
-5.27% 1681/3014 |
17.04% 1283/3129 |
-0.21% 1346/3463 |
| 2023 | -5.27% 724/2656 |
8.18% 485/2280 |
-3.95% 982/2385 |
-4.52% 1157/2515 |
-4.52% 1073/2655 |
| 2022 | -18.02% 651/2207 |
-13.89% 864/1919 |
3.57% 1132/2016 |
-10.74% 446/2113 |
2.97% 796/2208 |
| 2021 | 20.89% 173/1822 |
-0.96% 410/1255 |
11.01% 409/1330 |
5.75% 257/1466 |
3.98% 375/1822 |
| 2020 | 30.85% 515/1250 |
-2.99% 284/1028 |
18.51% 332/1067 |
9.00% 685/1164 |
4.42% 842/1184 |
| 2019 | 29.33% 506/1092 |
32.71% 168/754 |
-9.74% 685/804 |
0.74% 473/850 |
7.17% 475/918 |
| 2018 | -36.03% 584/834 |
- - |
- - |
- - |
-12.24% 427/691 |
| 2017 | -1.11% 492/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.89% 366/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证500ETF VS. 长安沪深300非周期A(740101) |